VIKING THERAPEUTICS • CLINICAL UPDATE

Get to know VK2735

The latest on an emerging obesity therapy

A dual GLP-1 / GIP receptor agonist

Weekly injection
Phase 2 efficacy

Daily oral tablet
Another route under study

Maintenance dosing
Early results worth following

Efficacy. Tolerability. What comes next.

Public evidence: Obesity 2026; Viking reports, 2025–2026
Investigational • not FDA-approved


Joseph Zucchi, PA-C, MPAS

PHASE 2 • VENTURE • PEER-REVIEWED

Weekly injection
13-week result

Mean weight loss (%) • 15 mg target dose

176 adults randomized • without diabetes



Adults with overweight/obesity • LS mean, mITT

Compare only with placebo in this study.

[1] Bays et al. • Obesity 2026 • doi:10.1002/oby.70106


Investigational • not FDA-approved

PHASE 2 • VENTURE-ORAL • TOPLINE

Daily oral tablet
13-week result

LS mean weight loss (%) • 120 mg target dose

280 randomized • overweight/obesity • no diabetes



7 weeks at 120 mg after dose escalation

Separate study; not a comparison with injection.

[2] Viking Therapeutics • 19 Aug 2025 • sponsor-reported


Investigational • not FDA-approved

PHASE 1 • EXPLORATORY MAINTENANCE

Less frequent dosing after weekly induction

21 weeks weekly → 12 weeks maintenance

Mean % of prior weight loss retained



Not the percentage of patients who maintained loss.

Small cohorts • adults with obesity • dose-range results

Monthly range includes one cohort with an outlier excluded.

[3] Viking Therapeutics • 22 Sep 2026 • sponsor-reported

Investigational • not FDA-approved

TOLERABILITY • 13-WEEK PHASE 2 TRIALS

Tolerability by dose

Stopped treatment because of adverse events


Weekly injection · VENTURE

Peer-reviewed • 35 per arm



Daily tablet · VENTURE-Oral

Conference poster • 40 per arm



Stopping medication did not necessarily mean leaving the study.

Separate trials; not a head-to-head safety comparison.

VENTURE: Obesity 2026, Table 3 • Oral: ECO 2026 poster

Investigational • not FDA-approved

WHAT COMES NEXT

Both formulations are now in Phase 3.

Longer trials will test durability and safety.

VANQUISH

Fully enrolled

Weekly injection • 78 weeks

Target doses: 7.5, 12.5 and 17.5 mg

SUNRISE

Trials initiated

Daily oral tablet • 68 weeks

Target doses: 27.5, 35 and 55 mg

Programs include adults with and without type 2 diabetes.

Oral-after-injection maintenance: Part 2 ongoing.

Next: durability, tolerability and dosing flexibility.

[4] Viking Therapeutics • 28 Oct 2026 • sponsor update
Investigational • not FDA-approved